Weight Loss Drug Shows Promises Of Treating Sleep Apnea

Eli Lilly's Zepbound showed potential to treat patients with the most common sleep-related breathing disorder in two late-stage clinical trials.

A study has shown that a weight-loss drug has potential to treat patients with sleep apnea.

Eli Lilly’s Zepbound showed potential to treat patients with the most common sleep-related breathing disorder in two late-stage clinical trials.

The drug appears to be more effective than a placebo at reducing the severity of obstructive sleep apnea, in patients with obesity after a year, according to data form both trials.

The results add to the list of potential health benefits of weight loss and diabetes treatments.

The pharmaceutical giant said it plans to present the results to the FDA later this year.